A 5-year multicentre randomized controlled trial comparing personalized, frozen and fresh blastocyst transfer in IVF by for the ERA-RCT Study Consortium Group
402 RBMO  VOLUME 41  ISSUE 3  2020
1 Department of Pediatrics, Obstetrics and Gynecology, University of Valencia, Valencia 46010, Spain
2 Igenomix Foundation-INCLIVA, Parque Tecnológico de Paterna, Ronda Narciso Monturiol Estarriol 11B, Paterna Valencia 
46980, Spain
3 Igenomix SL, Parque Tecnológico de Paterna, Ronda Narciso Monturiol Estarriol 11B, Paterna Valencia 46980, Spain
4 IVI-RMA Valencia, Plaza de la Policía Local 3, Valencia 46015, Spain
5 SBALAGRM-Sofia, 5 Baku St, Sofia 1756, Bulgaria
6 IVI-RMA Barcelona, Ronda General Mitre 14 Barcelona 08017, Spain
7 Bahçeci Health Group-Fulya IVF Centre, Hakki Yeten Cad, 11 Kat 3, Terrace Fulya Istanbul 34365, Turkey
8 IVI-RMA Madrid, Av Del Talgo 68, Aravaca Madrid 28023, Spain
9 Oak Clinic Japan, 2-7-9 Tamade-Nishi, Nishinari-ku Osaka 557-0045, Japan
10 ProcreaTec, Calle Manuel de Falla 6-8, Madrid 28036, Spain
11 IVI-RMA Vigo, Plaza Francisco Fernández del Riego 7, Vigo 36203, Spain
12 Nilo Frantz Reproductive Medicine, Av Dr Nilo Peçanha 1221 – 10° andar, Boa Vista Porto Alegre, Brazil
13 Centro de Infertilidade e Medicina Fetal do Norte Fluminense, R Barão da Lagoa Dourada 409 – Centro, Campos dos 
Goytacazes Rio de Janeiro 28035-210, Brazil
14 Department of Reproductive Medicine, Universitair Ziekenhuis Brussel, 101 Laarbeeklaan, Jette Brussels 1090, Belgium
15 IVI-RMA Panama, Calle 50 & Calle 57 Este, Panama City Panamá 07185
16 IVI-RMA Sevilla, Av República Argentina 58 Sevilla 41011, Spain
17 Departamento de Cirugía, Universidad de Sevilla, Avda. Sánchez Pizjuan S/N Sevilla 41009, Spain
18 Departamento de Biología Molecular e Ingeniería Bioquímica, Universidad Pablo de Olavide Sevilla 41013, Spain
19 IVI-RMA Bilbao, Leioa Paseo Landabarri 1Vizcaya 48940, Spain
20 Department of Obstetrics and Gynaecology, Monash University, Monash Medical Centre, 246 Clayton Road, Clayton 
Victoria 3168, Australia
†Joint first authors.
© 2020 The Authors. Published by Elsevier Ltd on behalf of Reproductive Healthcare Ltd. This is an open access article 
under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)
*Corresponding author. E-mail address: carlos.simon@uv.es (C.Simón). https://doi.org/10.1016/j.rbmo.2020.06.002 1472-
6483/© 2020 The Authors. Published by Elsevier Ltd on behalf of Reproductive Healthcare Ltd. This is an open access 
article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Declaration: CS is co-inventor of the patent for gene expression profile (ERA) issued to Igenomix and Head of the 
Scientific Advisory Board of Igenomix. EL reports grants from Finox, personal fees from Ferring, MSD, Angelini and 
Ovascience, and other non-financial support from Ferring, outside the submitted work. JA G-V reports grants from 
Merck, MSD, Ferring, Gedeon Richter, and Theramex, outside the submitted work. BM reports grant (GNT1082548) from 
the Australian National Health and Medical Research Council (NHMRC) related to the submitted work and personal fees 
from ObsEva and Merck KGaA, Geurbert and Merck, outside of the submitted work. CG, XS, M and DV are employees of 
Igenomix SL. Other authors declare no conflict of interest.
KEYWORDS
Endometrial receptivity
Endometrial receptivity analysis (ERA)
Fresh embryo transfer (ET)
Frozen embryo transfer (FET)
Personalized embryo transfer (PET)
Window of implantation (WOI)
ARTICLE
A 5-year multicentre randomized controlled 
trial comparing personalized, frozen and 
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KEY MESSAGE
This study demonstrates the clinical potential of personalized embryo transfer guided by the endometrial 
receptivity analysis test at the first appointment, which should be confirmed in larger randomized controlled trials.
ABSTRACT
Research question: Does clinical performance of personalized embryo transfer (PET) guided by endometrial receptivity 
analysis (ERA) differ from frozen embryo transfer (FET) or fresh embryo transfer in infertile patients undergoing IVF?
Design: Multicentre, open-label randomized controlled trial; 458 patients aged 37 years or younger undergoing IVF 
with blastocyst transfer at first appointment were randomized to PET guided by ERA, FET or fresh embryo transfer in 
16 reproductive clinics.
Results: Clinical outcomes by intention-to-treat analysis were comparable, but cumulative pregnancy rate was significantly 
higher in the PET (93.6%) compared with FET (79.7%) (P = 0.0005) and fresh embryo transfer groups (80.7%) 
(P = 0.0013). Analysis per protocol demonstrates that live birth rates at first embryo transfer were 56.2% in PET versus 
42.4% in FET (P = 0.09), and 45.7% in fresh embryo transfer groups (P = 0.17). Cumulative live birth rates after 12 months 
were 71.2% in PET versus 55.4% in FET (P = 0.04), and 48.9% in fresh embryo transfer (P = 0.003). Pregnancy rates at 
the first embryo transfer in PET, FET and fresh embryo transfer arms were 72.5% versus 54.3% (P = 0.01) and 58.5% 
(P = 0.05), respectively. Implantation rates at first embryo transfer were 57.3% versus 43.2% (P = 0.03), and 38.6% 
(P = 0.004), respectively. Obstetrical outcomes, type of delivery and neonatal outcomes were similar in all groups.
Conclusions: Despite 50% of patients dropping out compared with 30% initially planned, per protocol analysis demonstrates 
statistically significant improvement in pregnancy, implantation and cumulative live birth rates in PET compared with FET and 
fresh embryo transfer arms, indicating the potential utility of PET guided by the ERA test at the first appointment.
INTRODUCTION
When reproductive success or failure relies on collaboration between two partners, 
the functionality and synchronization 
of both are necessary. One reason 
why IVF treatments are not successful 
when good-quality embryos or even 
euploid embryos are transferred into the 
endometrial cavity (Rubio et al., 2017) 
may be due to the endometrial factor. 
Globally, IVF remains inefficient, with 
current live birth rates of only 25–30% 
per started cycle (Adamson et al., 2018); 
for comparison, rodents or rabbits have 
more than 95% implantation rate. The 
main difference lies in the endometrial 
and decidual control in human 
implantation events, versus embryo 
control in non-menstruating species 
(Simon and Giudice, 2017).
The endometrial mucosa is the 
anatomic and functional cellular 
mediator for embryonic implantation. 
Women menstruate in an endless 
resetting process to synchronize 
the uterus for the imminent arrival 
of a blastocyst. Progesterone is the 
single most important hormone 
controlling the initiation and course 
of pregnancy inducing the acquisition 
of a 12–48-h transient modification 
of the endometrial epithelium known 
as the window of implantation (WOI), 
demonstrated clinically (Navot et al., 
1991), epidemiologically (Wilcox et al., 
1999), and morphologically (Murphy 
et al., 2004). This limited period can 
be found from LH + 6 to LH + 9 in a 
natural cycle or from progesterone + 4 
to progesterone + 7 in a hormonal 
replacement therapy (HRT) cycle (Ruiz-
Alonso et al., 2013; 2014).
The transition from anatomical to 
molecular medicine has demonstrated 
the feasibility of an objective molecular 
classification of the human endometrium 
using transcriptomic profiling throughout 
the menstrual cycle (Ponnampalam 
et al., 2004; Talbi et al., 2006) as well 
as during the WOI (Riesewijk et al., 
2003). Precision medicine is focused 
on targeted individualized treatment. 
On this basis, in 2011, we reported the 
transcriptomic signature of human 
endometrial receptivity from 238 genes 
with an artificial intelligence platform and 
algorithm able to identify the WOI of 
a given patient, leading to the creation 
of the endometrial receptivity analysis 
(ERA) (Diaz-Gimeno et al., 2011; 2013). 
The clinical utility of ERA is in guiding a 
personalized embryo transfer (PET) by 
synchronizing the embryo with the WOI 
to the patient in a personalized manner 
for the initial indication of implantation 
failure of endometrial origin (Ruiz-Alonso 
et al., 2013; 2014; Mahajan et al., 2015; 
Hashimoto et al., 2017; Tan et al., 
2018). The goal is to improve clinical 
implantation by personalizing, diagnosing 
and synchronizing the endometrial factor.
In this multicentre, international, 
randomized controlled trial (RCT), 
infertile patients undergoing clinical 
evaluation for IVF were also assessed 
whether PET guided by the ERA test 
increased the probability of live birth, 
pregnancy and implantation rates versus 




An RCT evaluating PET guided by the 
ERA test versus FET or fresh embryo 
transfer. Participants were recruited 
from 16 reproductive clinics in Europe, 
USA and Asia, and randomized to 
one of the three arms indicated from 
25 November 2013 to 30 April 2017. 
All additional embryo transfers of the 
remaining cryopreserved embryos in 
the PET and FET arms as well as new 
fresh embryo transfers in the embryo 
transfer arm carried out within 1 year 
after the first embryo transfer were also 
included in the estimation of cumulative 
rates. Subsequently, all participants 
who conceived were followed through 
pregnancy up to delivery; obstetric and 
neonatal outcomes were also reported. 
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Data on pregnancy outcome were 
prospectively collected from the clinical 
sites involved and entered them into a 
secure electronic database.
Ethical approval
Ethical approval was given by Instituto 
Valenciano de Infertilidad Ethics 
Committee (2 July 2013), Spain; Local 
Ethics Commission of SBALAGRM – Sofia 
(29 January 2014), Bulgaria; UZ Brussels 
Medical Ethics Committee, Belgium (26 
February 2014 with code 2014/006); 
Instituto Conmemorativo Gorgas de 
Estudios de la Salud Ethics Committee 
Panama 26 February 2014 with code 214/
CBI/ICGES/14); Istanbul Bilim Üniversitesi 
Klinik Arastirmalari Ethics Committee, 
Turkey (28 May 2014 with code 
28.05.2014/20-145); Hospital das Clínicas 
da Faculdade de Medicina da USP Ethics 
Committee Brazil 3 December 2015 
with code 1.349.189; Oak Clinic Group's 
Ethics Committee, Japan (28 February 
2016). Each participating site provided a 
site-specific approval, and all participants 
provided written informed consent. Data 
were monitored by a clinical research 
associate. The protocol was first registered 
on 7 October 2013, and the first patient 
recruited on 25 November 2013 
(ClinicalTrials.gov ID NCT01954758).
Participants
Infertile patients undergoing IVF were 
recruited at their first appointment. 
Women scheduled for embryo transfer 
at the blastocyst stage (day 5 or 6) were 
included. Inclusion criteria were age 
37 years or younger, body mass index 
(BMI) of 18.5–30 and normal ovarian 
reserve (antral follicle count ≥8 and 
FSH <8 IU/ml). Ovarian stimulation 
protocol was decided by the enrolling 
physician, and the blastocyst vitrification 
system was the one used by the clinic. 
Couples who had experienced recurrent 
miscarriage (more than two previous 
biochemical pregnancies or spontaneous 
abortions), implantation failure (more 
than three failed IVF cycles with good-
quality embryos transferred) or who 
had severe male factor infertility (fewer 
than 2 million spermatozoa/ml) were 
not eligible. Pathology affecting the 
endometrial cavity, including polyps and 
submucosal myomas, intramural myomas 
over 4 cm or hydrosalpinx previously 
operated on before embryo transfer, 
was not an exclusion criterion. Couples 
using preimplantation genetic diagnosis 
for aneuploidy (PGT-A) could also 
participate.
Post-randomization exclusion criteria 
were progesterone levels of over 1.5 ng/
ml on the day of HCG administration 
in all groups, absence of blastocysts 
(day 5 or 6) for embryo transfer, or risk 
of ovarian hyperstimulation syndrome 
(OHSS) in the fresh embryo transfer 
arm. For all these cases, patients did not 
enter the per protocol analysis but were 
included in the intention-to-treat analysis.
During the first appointment in each 
participating site and after providing 
informed consent, suitable patients were 
randomized into either PET, FET or 
fresh embryo transfer groups. In the FET 
group, patients received transfer during 
a hormonal replacement therapy (HRT) 
cycle after embryo thawing, following the 
protocol and timing used in each clinic.
Ovarian stimulation, embryo culture 
and vitrification
In all groups, ovarian stimulation was 
carried out using standard protocols in 
each of the participant sites according 
to female age, basal hormone levels, 
basal ovarian reserve and BMI. After a 
normal basal ultrasound, gonadotrophins 
were administered from day 2–3 after 
menstruation. Serial transvaginal 
ultrasound examinations and serum 
oestradiol determination were started 
on day 5 of ovarian stimulation and 
repeated every 48 h to monitor the 
ovarian response. Ovulation triggering 
was carried out mainly with HCG 
administration or gonadotrophin 
releasing hormone agonist, depending on 
the gonadotrophin protocol used, when 
at least two follicles reached 18 mm. 
Oocyte retrieval was scheduled 36 h 
later.
Intracytoplasmic sperm injection (ICSI) 
or IVF was carried out according to the 
protocols of the participating sites, and 
fertilization was assessed 17–20 h after 
insemination or microinjection. Embryos 
were cultured using different approaches 
and culture media depending on the 
IVF laboratory. Embryo morphology 
and quality were evaluated according 
to Gardner's criteria (Gardner et al., 
2007). Properly developed blastocysts 
were transferred on day 5 or 6 in 
the fresh embryo transfer arm, or 
vitrified in the PET and FET arms, using 
different protocols depending of the 
IVF laboratory. Subsequent blastocyst 
transfer was carried out at each 
participant site with different types of 
transfer catheters.
Personalized embryo transfer guided 
by endometrial receptivity analysis
In the PET group, patients underwent 
one or two endometrial biopsies (the 
timing of the second biopsy depended 
on the first result), and embryo transfer 
was carried out in an HRT cycle at the 
timing indicated by the ERA test.
Endometrial biopsies were collected 
from the uterine fundus using a Pipelle 
catheter from Cornier® devices (CCD 
Laboratories, Paris, France) or similar, 
under sterile conditions. After the biopsy, 
the endometrial tissue was transferred 
to a cryotube containing 1.5 ml of 
RNALater (QIAGEN, Barcelona, Spain), 
vigorously shaken for a few seconds, and 
kept at 4°C or in ice for at least 4 h. 
The samples were then shipped at room 
temperature for ERA test.
Endometrial preparation for frozen 
embryo transfer and personalized 
embryo transfer
The endometrium was prepared for 
the cycle to carry out the ERA test, 
and subsequent PET and FET were 
carried out using an HRT cycle, as 
previously described (Ruiz-Alonso et al., 
2013;2014). Briefly, after menstruation, 
ovarian quiescence was confirmed 
by vaginal ultrasound evaluation and 
oestradiol administration started from 
the second or third day onwards. 
Sonographic evaluation and oestradiol 
and progesterone assessment were 
carried out between 7 and 10 days after 
endometrial oestradiol preparation 
treatment. When a trilaminar 
endometrium measuring 6 mm or 
more with an endogenous progesterone 
serum level close to zero was observed, 
progesterone was administered at 
dosage and route of the participant 
physician or clinic for a period of 
5 days (progesterone + 5 or 120 h, 
approximately).
Fresh embryo transfer
Embryo transfer in fresh cycles was 
carried out 5 or 6 days after oocyte 
retrieval according to blastocyst timing. 
Luteal phase supplementation route 
and dosage was the one used by the 
participant physician or clinic.
Sample labelling, hybridization 
and personalized embryo transfer 
recommendation
Total RNA was extracted using the TRIzol 
method according to the manufacturer's 
protocol (Life Technologies, Inc., 
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Carlsbad, CA, USA). About 1–2 µg of 
total RNA were obtained per mg of 
endometrial tissue. RNA quality was 
assessed by loading 300 ng of total RNA 
onto an RNA Labchip and analysing 
it in an A2100 Bioanalyzer according 
to manufacturer's protocol (Agilent 
Technologies, Inc., Santa Clara, CA, 
USA). Good-quality RNA samples, with 
RNA integrity number greater than 7, 
was a prerequisite for ERA. Sample 
preparation and hybridization was 
adapted from the Agilent technical 
manual (one-color). In short, first strand 
cDNA was transcribed from 200 ng of 
total RNA using T7-Oligo(dT) Promoter 
Primers. Samples were transcribed 
in vitro, and Cy-3 labelled, all with a 
Low Input Quick Amp Labeling kit 
(Agilent Technologies, Inc., Santa 
Clara, CA, USA). The labelling reaction 
typically yielded between 4 and 5 µg 
of complementary RNA with a specific 
activity greater than 6. Fragmented 
complementary RNA samples were 
hybridized onto the customized ERA 
microarray (Diaz-Gimeno et al., 2011), 
by incubation at 65°C for 17 h with 
constant rotation. The microarray was 
then washed with two 1-min steps in 
two different washing buffers (Agilent 
Technologies, Inc., Santa Clara, CA, 
USA). Hybridized microarrays were 
scanned in an Axon 4100A scanner 
(Molecular Devices, Sunnyvale, CA, 
USA), and data were extracted with the 
GenePix Pro 6.0 software (Molecular 
Devices, Sunnyvale, CA, USA). 
Endometrial receptivity analysis gene 
expression values were pre-processed 
and normalized, and the endometrial 
receptivity status was diagnosed by the 
ERA computational predictor (Díaz-
Gimeno et al., 2011). The ERA test 
diagnoses an endometrial sample as 
receptive, pre-receptive or post-receptive 
with an associated diagnostic probability. 
This provides a recommendation for 
PET in a particular patient at P + 4, 
P + 4.5, P + 5, P + 5.5, P + 6, or P + 7. 
As described previously (Díaz-Gimeno 
et al., 2011), the customized microarray 
for ERA was designed after selecting 238 
genes involved in human endometrial 
receptivity based on different gene 
expression profiles across the receptive, 
pre-receptive and post-receptive stages 
using raw expression data generated for 
a previous publication from our group. 
Genes showing an absolute fold-change 
greater than 3 and a false discovery 
rate less than 0.05 were selected. 
Three statistical approaches were used 
to generate the prediction: the union 
of the T-Rex gene list (GEPAS) (http://
gepas.bioinfo.cipf.es/) and SAM gene 
list (http://www.stat.stanford.edu/_tibs/
SAM/), intersected with the multtest 
gene list (http://www.bioconductor.
org/). Selected genes were included in a 
customized gene expression microarray 
with a 15Kx8 format by using 4.5 earray 
(https://earray.chem.agilent.com/earray/). 
All the probes included in ERA were 
selected from Agilent's catalogue to 
avoid crosslinking phenomena. The ERA 
predictor was based on support vector 
machine prediction with a specificity 
and sensitivity of 0.886 and 0.998, 
respectively (Diaz-Gimeno et al., 2011).
Outcome measures
Primary outcome was live birth rate (LBR) 
after the first embryo transfer. Secondary 
outcomes were cumulative LBR (CLBR), 
pregnancy rate and implantation rate, 
both at the first embryo transfer and 
cumulative rates after 1-year follow-up. 
Percentages of biochemical pregnancy, 
clinical miscarriage and ectopic 
pregnancy from the total number of 
beta-HCG-positive patients as well 
as obstetric, delivery and neonatal 
outcomes were also reported.
According to the International Glossary 
on Infertility and Fertility Care (Zegers-
Hochschild, et al., 2017), the following 
standardized definitions were considered.
Pregnancy rate
Pregnancy rate is the number of patients 
with positive serum level of beta-HCG 
(≥25 mIU/ml) per embryo transfer.
Live birth rate
The LBR is the number of deliveries 
that resulted in at least one live birth 
per embryo transfer. Live birth is 
defined as the complete expulsion or 
extraction from a woman of a product of 
conception after 22 weeks of gestation, 
which, after such separation, breathes or 
shows any other evidence of life, such as 
heart beat, umbilical cord pulsation or 
definite movement of voluntary muscles, 
irrespective of whether the umbilical 
cord has been cut or the placenta is 
attached.
Implantation rate
The implantation rate is the number 
of gestational sacs observed by vaginal 
ultrasound at the fifth gestational week 
divided by the number of embryos 
transferred.
Clinical miscarriage rate
The clinical miscarriage rate is the 
number of spontaneous pregnancy 
losses in which a gestational sac or sacs 
was previously observed, per number of 
pregnancies.
Biochemical pregnancy rate
The biochemical pregnancy rate is 
the number of pregnancies diagnosed 
only by beta-HCG detection without 
a gestational sac visualized by vaginal 
ultrasound at the fifth week of pregnancy, 
per number of pregnancies.
Ectopic pregnancy rate
The ectopic pregnancy rate is the 
number of pregnancies outside the 
uterine cavity, diagnosed by ultrasound, 
surgical visualization or histopathology, 
per number of pregnancies. For 
cumulative outcomes, we considered 
the clinical results obtained from all 
the embryo transfers performed in the 
same arm of the study up to 12 months 
follow-up.
Cumulative pregnancy rate
The cumulative pregnancy rate (CPR) 
is the number of patients with positive 
serum level of beta HCG 25 mIU/ml or 
above divided by the total number of 
patients receiving embryo transfer after 
the same type of transfer arm into which 
the patient was randomized for up to 12 
months’ follow-up.
Cumulative live birth rate
The CLBR is the number of deliveries 
that resulted in at least one live birth (as 
previously defined), per total number 
of patients receiving embryo transfer 
following the same type of transfer arm 
into which the patient was randomized 
for up to 12 months’ follow-up.
All clinical outcomes are presented 
as percentages. Patients with positive 
pregnancy tests were followed to delivery. 
Patients without pregnancy, clinical or 
biochemical miscarriages, or both, or 
ectopic pregnancies, were followed up to 
12 months after the first embryo transfer 
to calculate the cumulative outcomes.
Sample size calculation and statistical 
analysis
Sample size calculation was based on 
the hypothesis of 15-percentage point 
absolute difference in primary and 
secondary endpoints (alpha = 5%; 
beta = 20%) in the study group (PET) 
versus FET and fresh embryo transfer. 
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This analysis was carried out using a SPSS 
Macro for one-sided significance level 
analysis, resulting in a sample size of at 
least 130 patients per group. Because 
of the multicentre and international 
nature of the study, a 30% drop-out rate 
was estimated owing to possible loss to 
follow-up, no blastocyst for transfer or 
no protocol compliance. Therefore, a 
plan was made to recruit a total of 546 
patients, corresponding to 182 patients 
per group. This was a non-blinded study; 
all participants were assigned to each of 
the three arms using a simple equal-
probability randomization method. A 
software-based application was used 
to allocate intervention (1:1:1) with 
randomization stratified by site.
Analyses on an intention-to-treat and 
per protocol basis were conducted for 
all data. Repeated measures analysis of 
variance was used to compare non-
categorical variables among the three 
groups, multiple comparisons and 
post-hoc tests (Bonferroni and two-
sided Dunnett) were applied for each 
one to one group comparisons. Mean 
differences and standard deviation or 
median and interquartile ranges were 
used when the variables were not 
homogeneous, as well as the mean 
difference with 95% CI values. Chi-
squared test and two-sided Fisher's exact 
test were used to compare the study 
groups with respect to percentages. 
Differences were estimated as relative 
risks with 95% CI. We conducted a 
multivariable regression analysis with a 
binomial endpoint (live birth Yes/No) to 
demonstrate the homogeneity of the key 
baseline variables and the absence of bias 
towards our final endpoint. We included 
all baseline variables presented in TABLE 1 
as follows: age, body mass index, site, 
FSH, anti-Müllerian hormone, ethnicity 
and fertility background.
P < 0.05 was considered to be 
statistically significant. SPSS 25 software 
(IBM, MD, USA) was used for statistical 
analysis.
RESULTS
Between 25 November 2013 and 30 
April 2017 569 patients were assessed 
for eligibility (FIGURE 1). One hundred 
and eleven patients were excluded 
from randomization because they did 
not meet the inclusion criteria (n = 51), 
declined to participate (n = 43) or 
were double-randomized by mistake (n 
=8), or an inclusion error was detected 
(n = 9). The remaining 458 women were 
randomly assigned to either PET guided 
by the ERA (n = 148), FET (n = 154) or 
fresh embryo transfer) (n = 156).
Loss to follow-up occurred in 24 patients, 
27 did not receive blastocyst transfer 
(16 had no blastocyst, six spontaneous 
pregnancies occurred, two were 
cancelled owing to OHSS risk, and, in 
three cases, no embryo transfer data 
were found), and 139 did not fully comply 
with the protocol (seven had no PET in 
the PET group, six had PET in the non-
PET groups, 43 had high progesterone, 
21 had fresh embryo transfer on day 2, 3 
or 4, 10 and seven had fresh and frozen 
embryo transfer in the PET group, 22 
had fresh embryo transfer in the FET 
group, six had frozen embryo transfer in 
the embryo transfer group, 13 had frozen 
embryo transfer owing to OHSS risk in 
the fresh embryo transfer group, four 
protocol deviations for other reasons). 
The intention to treat (ITT) analysis was 
conducted in 434 patients, PET (n = 141), 
FET (n = 148) or fresh embryo transfer 
(n = 145). Per protocol analysis was 
conducted in 266 patients (PET [n = 80], 
FET [n = 92] or fresh embryo transfer 
[n = 94]) (FIGURE 1).
Baseline demographics and clinical 
characteristics were comparable among 
groups, both at the ITT and per protocol 
analysis (TABLE 1). The FSH values were 
similar between PET and FET groups 
and higher compared with fresh embryo 
transfer group. About 71% of the patients 
recruited at their first appointment had 
no previous IVF attempts.
Intention-to-treat analysis of cycle 
characteristics and embryological data 
were also broadly similar in all groups 
(TABLE 2). A statistically significant lower 
percentage of day-5 blastocysts, however, 
was transferred in the PET group 
compared with fresh embryo transfer 
(69.5% versus 82.1%, respectively; 
P = 0.01). Similar features were observed 
by per protocol analysis, where a 
significantly lower percentage of day-5 
blastocysts was transferred in the PET 
and FET group compared with fresh 
embryo transfer (85.0% and 84.8% 
versus 96.8%, respectively; P = 0.01 
(Supplementary Table 1), together with a 
significantly lower number of transferred 
embryos in the PET versus embryo 
transfer arms (1.38 versus 1.6; P = 0.01). 
No morphological differences were 
recorded in embryo quality in terms 
of inner cell mass or trophectoderm 
grading.
Clinical outcomes at the first embryo 
transfer and cumulative rates up to 
12 months by ITT analysis are shown 
in TABLE 3. In the PET group, CPR was 
significantly higher (132/141 [93.6%]) 
compared with FET (118/148 [79.7%]) and 
fresh embryo transfer (117/145 [80.7%]) 
groups (PET versus FET RR 1.17, 95% 
CI 1.07 to 1.29, P = 0.0005; PET versus 
fresh embryo transfer RR 1.16, 95% CI 
1.06 to 1.27, P = 0.0013). Significantly 
more miscarriages took place in the PET 
than the fresh embryo transfer group 
at the first attempt (20.5% versus 5.9% 
P = 0.006) and cumulative miscarriage 
rate (18.2% versus 4.3%, P = 0.0006) 
(TABLE 3).
Per protocol analysis is presented in 
TABLE 4. At first embryo transfer, LBR was 
45 out of 80 (56.2%) in the PET group, 
39 out of 92 (42.4%) in the FET group, 
and 43 out of 94 (45.7%) in the fresh 
embryo transfer group (PET versus FET 
RR 1.33, 95% CI 0.98 to 1.80, P = 0.09; 
PET versus fresh embryo transfer RR 
1.23, 95% CI 0.92 to 1.65, P = 0.17). 
The number of patients needed to treat 
(NNT) by ERA (PET) to achieve the 
estimated LBR versus the control groups 
(FET and fresh embryo transfer) was 
calculated according to NNT= 100/Io-Ie 
(where Io is the LBR in the control group 
and Ie is the LBR in the study group). 
NNT of PET versus FET was 7.2 patients 
(Io = 42.4; Ie = 56.2), and NNT of PET 
versus fresh embryo transfer was 9.5 
patients (Io = 45.7; Ie = 56.2); thus, these 
were the numbers of patients needed 
to treat by ERA (PET) to achieve one 
additional delivery with at least one live 
birth versus control groups.
The CLBR was significantly higher in 
the PET group (71.2%) compared with 
FET (55.4%) and fresh embryo transfer 
(48.9%) groups (PET versus FET, RR 
1.28, 95% CI 1.02 to 1.62, P = 0.04; PET 
versus fresh embryo transfer RR 1.46, 
95% CI 1.13 to 1.87, P = 0.003).
Pregnancy rate at the first embryo 
transfer was statistically significantly 
higher in the PET group versus FET. 
Pregnancy rate was 72.5% in the PET 
group, 54.3% in the FET group and 
58.5% in the fresh embryo transfer group 
(PET versus FET, RR 1.33, 95% CI 1.06 to 
1.68, P = 0.01; PET versus fresh embryo 
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transfer, RR 1.24, CI 1 to 1.54, P = 0.057). 
Statistically significant differences were 
also found in implantation rate in PET 
(57.3%) versus FET (43.2%) and fresh 
embryo transfer (38.6%) groups (PET 
versus FET, RR 1.33, 95% CI 1.03 to 
1.70, P = 0.03; PET versus fresh embryo 
transfer, RR 1.48, 95% CI 1.14 to 1.92, 
P = 0.004). Cumulative pregnancy rate 
in the PET group (95%) was significantly 
higher than FET (70.6%) and fresh 
embryo transfer (62.8%) groups (PET 
TABLE 1 DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF THE PATIENTS AT BASELINE
PET (n = 148) FET (n = 154) Fresh embryo transfer (n = 156)
Age, years 33 ± 3.1 32.8 ± 3.4 32.7 ± 3.3
Body mass indexa 22.8 ± 2.9 22.9 ± 2.9 22.6 ± 2.8
Ethnicity, n %
 White 122 (82.4) 127 (82.5) 129 (82.7)
 Asian 12 (8.1) 12 (7.8) 11 (7.1)
 Latin American 13 (8.8) 11 (7.1) 13 (8.3)
 African 0 (0.0) 4 (2.6) 1 (0.6)
 Other or unknow 1 (0.6) 0 (0.0) 2 (1.2)
Current smoker 15 (10.1) 12 (7.8) 15 (9.6)
Fertility history
 Duration of infertility, years 3.1 ± 1.9 3.2 ± 2.1 2.9 ± 2.2
 Previous IVF failed, n (%)
  0 109 (73.6) 104 (67.5) 112 (71.8)
  1 20 (13.5) 23 (14.9) 22 (14.1)
  2 10 (6.7) 10 (6.5) 12 (7.7)
  3 6 (4.0) 11 (7.1) 6 (3.8)
  Unknown 3 (2.0) 6 (3.9) 4 (2.6)
 Previous deliveries, n (%)
  1 11 (7.4) 16 (10.3) 17 (10.9)
  ≥2 3 (2.0) 4 (2.6) 3 (1.9)
 Spontaneous clinical miscarriages, n (%)
  1 23 (15.5) 26 (16.9) 24 (15.4)
  ≥2 6 (4.0) 3 (1.9) 0 (0.0)
 Elective abortions, n (%) 3 (2.0) 9 (5.8) 8 (5.1)
 Previous curettages (1 or 2), n (%) 12 (8.1) 11 (7.1) 10 (6.4)
 Ectopic pregnancies, n (%) 8 (5.4) 3 (1.9) 4 (2.6)
 IVF indication, n %
 Male factor 65 (43.9) 78 (50.6) 50 (32.1)
 Tubal factor 20 (13.5) 31 (20.1) 33 (21.1)
 PCOS 27 (18.2) 20 (12.9) 14 (9.0)
 Ovarian disorders 4 (2.7) 5 (3.2) 7 (4.5)
 Endometriosis 21 (14.2) 9 (5.8) 13 (8.3)
 Unexplained 33 (22.3) 33 (21.4) 47 (30.1)
 Other or unknownb 2 (1.3) 4 (2.6) 10 (6.4)
Laboratory tests
 FSH (mU/ml) 5.9 ± 1.9c 6.6 ± 2.1 6.9 ± 2.0d
 AMH (ng/nl) 4.4 ± 3.6 3.7 ± 2.7 3.5 ± 2.9
Data are expressed as mean ± SD unless indicated otherwise.
a Body-mass index is the weight in kilograms divided by the square of the height in metres.
b Other indications included same sex couples, single women, cervical factor, anatomical factor and male genetic disease.
c,dStatistically significant differences between groups at <0.05 level. No significant differences were found in any of the baseline characteristics except for FSH between PET 
and fresh embryo transfer (P = 0.003).
Analysis of variance, Bonferroni and two-sided Dunnett tests were used to compare numerical variables in the three groups. Chi-Squared and Fisher's exact tests were used 
to compare categorical variables.
AMH, anti-Müllerian hormone; FET, frozen embryo transfer; PCOS, polycystic ovary syndrome.; PET, personalized embryo transfer.
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versus FET, RR 1.34, 95% CI 1.17 to 1.55, 
P < 0.0001; PET versus fresh embryo 
transfer, RR 1.51, 95% CI 1.28 to 1.78, 
P < 0.0001) (TABLE 4). For cumulative 
clinical outcomes (after the first attempt), 
most of the pregnancies and live births 
occurred in the second and third embryo 
transfer (Supplementary Table 2). No 
differences were found in miscarriages, 
biochemical or ectopic pregnancies 
among the three groups investigated 
(TABLE 4). Obstetrical outcomes, type of 
delivery and neonatal outcomes were 
not statistically significant different in all 
groups analysed (TABLE 5). The binomial 
multivariable regression analysis did not 
show any statistical relation between LBR 
and the rest of variables included in the 
study (data not shown).
Subgroup analysis of clinical outcome 
was investigated according to the 
number of previous failed IVF cycles. 
The LBR and pregnancy rate in the 
PET group were consistently 10 or 
more percentage points higher in all 
categories regardless of the previous 
failed cycles but did not reach 
significance owing to the final sample 
size (Supplementary Table 3). Clinical 
results were also analysed according to 
time from endometrial biopsy carried 
out for the ERA test to transfer for a 
period of 9 months. Pregnancy rate 
and LBR were not statistically different 
throughout this period, ruling out any 
beneficial or detrimental effect of the 
injury carried out at endometrial biopsy 
(Supplementary Table 4).
The ERA biopsy was obtained after 118.3 
± 4.6 h of progesterone administration 
(range 108 to 128 h). Results showed 
that 50 patients (62.50%) had the WOI 
at P + 5, whereas 30 out of 80 (37.5%) 
had a displaced WOI (early receptive 
[n = 5], late receptive [n = 18] and 
pre-receptive [n = 7]). In the PET arm, 
patients underwent embryo transfer 
according to ERA results; primary and 
secondary clinical outcomes were similar 
irrespective of whether PET was carried 
out in non-displaced (56% LBR [n = 50]) 
or displaced (56.7% LBR [n = 30]) WOI 
(Supplementary Table 5).
Cost-effectiveness per baby born in 
Europe and the USA was also calculated 
in each arm of the study, using as 
reference the mean cost of procedures 
in these two geographical locations. This 
assessment considered the cost of the 
different procedures involved in each 
arm of the study. In all arms, the cost of 
monitoring, retrieval, transfer, drugs and 
IVF laboratory was included. In FET and 
PET, the cost of embryo vitrification and 
HRT monitoring with laboratory work was 
added. Finally, in the PET arm, the cost 
of the ERA test plus the additional HRT 
was incorporated. The cost per baby in 
the PET arm considering the technology 
used in the present study was lower than 
the FET arm (17% in Europe and 15% in 
USA, approximate) and higher compared 
with fresh embryo transfer (25% in 
Europe and 16% in USA, approximate) 
(TABLE 6).
DISCUSSION
This international, multicentre RCT 
was designed to test the effect of the 
endometrial factor assessed by the ERA 
test and clinically translated as PET. The 
first inclusion criterion was patients aged 
37 years or younger to avoid advanced 
maternal age as a possible cause of 
embryo aneuploidies that could bias 
the results because of the embryonic 
factor; the same rationale applies for 
antral follicle count 8 or over and FSH 
less than 8 IU/ml to avoid the inclusion of 
poor responders. In these overall good-
prognosis patients, clinical outcomes at 
the first embryo transfer and cumulative 
569 assessed for eligibility
458 randomized
111 were excluded
     50 did not meet selection criteria
     43 declined to participate
     8 double randomization by mistake
     9 inclusion errors
Enrolment















156 allocated to fresh ET
141 followed up
81 proceeded with PET
1 pregnancy termination for medical reasons
80 followed up after the first embryo transfer
51 no protocol compliance
     1 embryo day-3 embryo transfer
     5 embryo day-4 embryo transfer
     10 had fresh embryo transfer
     7 had FET
     18 high progesterol in
          ovarian stimulation
     7 no PET
     2 other treatment (INVO)
     1 protocol deviation
11 did not receive embryo transfer
     2 no to embryo transfer data
     6 no blastocyst for embryo transfer
     3 spontaneous pregnancy
7 lost to follow-up
148 followed up
92 proceeded with FET
92 followed up after the first
embryo transfer
148 ITT analysis
92 per protocol analysis
145 ITT analysis
94 per protocol analysis
45 no protocol compliance
     3 embryo day-3 embryo transfer
     1 embryo day-4 embryo transfer
     22 had fresh embryo transfer
     5 had PET
     13 high progesterone
          in ovarian stimulation
     1 ovum donation
145 followed up
11 lost to follow-up
95 proceeded with fresh embryo transfer
94 followed up after the first embryo transfer
1 pregnancy termination for medical reasnons
43 no protocol compliance
     2 embryo day-2 embryo transfer
     8 embryo day-3 embryo transfer
     1 embryo day-4 embryo transfer and high
        progesterone ovarian stimulation
     6 had FET
     13 had FET owing OHSS risk
     1 had PET
     12 high progesterone in ovarian stimulation
7 did not received embryo transfer
     1 no embryo transfer data
     3 no blastocyst for embryo transfer
     2 cancelled owing to OHSS risk
     1 spontaneous pregnancy
138 proceeded with
embryo transfer137 proceeded wth
embryo transfer
6 lost to follow up
9 did not receive embryo transfer
     7 no blastocyst for embryo transfer
     2 spontaneous pregnancy132 proceed with
embryo transfer
141 ITT analysis
80 per protocol analysis
FIGURE 1 CONSORT flow diagram: endometrial receptivity analysis randomized controlled trial. FET, frozen embryo transfer; INVO, intravaginal 
culture of oocytes; ITT, intention-to-treat; OHSS, ovarian hyperstimulation syndrome; PET, personalized embryo transfer.
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TABLE 2 CYCLE CHARACTERISTICS AND EMBRYOLOGICAL DATA: INTENTION-TO-TREAT ANALYSIS
PET (n = 141) FET (n = 148) Fresh embryo transfer (n = 145)
 Antral follicle count 14.8 ± 6.3 14.9 ± 6.6 13.1 ± 5.9
 Antagonist protocol, n (%) 124 (87.9) 120 (81.1) 122 (84.1)
 Agonist protocol, n (%) 10 (7.1) 13 (8.8) 12 (8.3)
 Unknown, n (%) 7 (5.0) 15 (10.1) 11 (7.6)
Total dose of FSH administered, IU 1696.9 ± 687.8 1540.2 ± 635.2 1666.1 ± 669.8
Total dose of HMG administered, IU 1167.03 ± 936 1202.3 ± 987 1165.1 ± 1042.5
Progesterone level at the day of ovulation triggering 1.02 ± 0.7 0.93 ± 0.6 0.92 ± 0.8
Ovulation triggering, n (%)
 HCG 62 (44.0)c 57 (38.5)c 110 (75.9)d
 Agonist 62 (44.0)c 67 (45.3)c 15 (10.3)d
 Double triggering 7 (5.0) 7 (4.7) 7 (4.8)
Oocytes retrieved 12.4 ± 7.6 11.6 ± 6.0 10.5 ± 6.6
Fertilization technique, n (%)
 ICSI 106 (75.2) 114 (77.0) 111 (76.6)
 IVF 5 (3.5) 6 (4.1) 9 (6.2)
 IVF/ICSI 21 (14.9) 13 (8.8) 21 (14.5)
 INVO 2 (1.4) 0 (0.0) 0 (0.0)
 Unknown 7 (5.0) 15 (10.1) 4 (2.8)
Fertilization rate, n (%) 1244/1633 (76.2) 1197/1531 (78.2) 1067/1379 (77.4)
Embryo stage, n (%)
 Cleavage 1/181 (0.6) 0 (0.0)c 7/211 (3.3)d
 Morula 2/181 (1.1) 1/208 (0.5) 1/211 (0.5)
 Early blastocyst 12/181 (6.6) 11/208 (5.3) 5/211 (2.4)
 Cavitated blastocyst 40/181 (22.1) 47/208 (22.6) 48/211 (22.7)
 Expanded blastocyst 93/181 (51.4) 100/208 (48.1) 109/211 (51.7)
 Hatching blastocyst 33/181 (18.2) 49/208 (23.6) 41/211 (19.4)
Blastocyst development rate, n (%) 648/1248 (51.9) 636/1239 (51.3) 561/1093 (51.3)
Day of embryo development at transfer, n (%)a
 2 0 (0.0) 0 (0.0) 2 (1.4)
 3 10 (7.1) 4 (2.7) 10 (6.9)
 4 7 (5.0)c 4 (2.7) 0 (0.0)d
 5 98 (69.5)c 112 (75.7) 119 (82.1)d
 6 16 (11.3) 17 (11.5)c 6 (4.1)d
Unknown, n (%) 10 (7.1) 11 (7.4) 8 (5.5)
Embryo quality (known/total embryos), n 149/201 183/220 183/225
 Inner cell mass, n (%)
 A grade 48/149 (32.2) 70/183 (38.3) 56/183 (30.6)
 B grade 84/149 (56.4) 92/183 (50.3) 110/183 (60.1)
 C grade 17/149 (11.4) 21/183 (11.5) 17/183 (9.3)
 Trophectoderm, n (%)
 A grade 36/149 (24.2) 56/183 (30.6) 46/183 (25.1)
 B grade 85/149 (57) 95/183 (51.9) 96/183 (52.5)
 C grade 28/149 (18.8) 32/183 (17.5) 40/183 (21.9)
PGT-A cases 6 (4.3) 4 (2.7) 3 (2.1)
Number of embryos per transfer 1.52 ± 0.5 1.61 ± 0.5 1.63 ± 0.5
(continued on next page)
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rates up to 12 months by ITT analysis 
were not statistically significant in the 
three arms of the study, except that CPR 
that was significantly higher in the PET 
group compared with FET and fresh 
embryo transfer groups, and clinical 
miscarriages were significantly higher in 
PET versus fresh embryo transfer.
When the analysis was carried out per 
protocol, LBR significance in PET versus 
FET and fresh embryo transfer was not 
achieved at the first embryo transfer 
(56.2%, 42.4%, 45.7%, respectively; PET 
versus FET, P = 0.09; PET versus fresh 
embryo transfer, P = 0.17). Significantly 
higher CLBR after 12 months’ follow-up 
from PET versus FET and fresh embryo 
transfer, however, were observed (71.2%, 
55.4%, 48.9%, respectively; PET versus 
FET, P = 0.04; PET versus fresh embryo 
transfer; P = 0.003). Implantation rate 
at first attempt was significantly higher in 
PET compared with FET and fresh embryo 
transfer. In addition, pregnancy rate after 
PET was significantly higher than FET at 
the first attempt and significantly higher 
than FET and fresh embryo transfer at 
cumulative rate (TABLE 4).
The delivery of a healthy baby may take 
several treatment cycles; therefore, 
the CLBR per patient is a key outcome 
variable. To ensure that results are 
presented without bias, a statistical 
comparison was made of CLBR for each of 
the four cycles carried out in each arm of 
the study regardless of the follow-up time 
(Supplementary Table 2). The significant 
difference in CLBR in PET can be 
observed at the second embryo transfer.
In the PET arm, outcomes were similar 
in the non-displaced (n = 50; LBR 56%) 
and the displaced group (n = 30; LBR 
56.7%), indicating the importance of 
a timely PET. More than 45,500 data 
and variables corresponding to the 
569 patients enrolled in the 16 active 
sites across continents were recorded 
in the study Case Report Form. These 
data were verified according to each 
patient source document during 
the continuous on-site and remote 
monitoring visits. This exhaustive source 
data verification allowed us to detect 
and correct mistakes and protocol 
deviations as well as to resolve queries, 
ensuring the study data integrity and 
accuracy.
The study was powered to detect 
statistical differences for a 15-percentage 
point increase in the primary and 
secondary outcomes in the PET group 
guided by ERA versus FET or fresh 
embryo transfer. This unexpected dilution 
was the main reason why LBR significance 
in PET versus FET and fresh embryo 
transfer was not achieved at the first 
embryo transfer (56.2%, 42.4%, 45.7%, 
respectively; PET versus FET, P = 0.09; 
PET versus fresh embryo transfer; 
P = 0.17) (TABLE 4).
The significantly lower number of 
blastocysts transferred in the PET arm 
versus fresh embryo transfer (1.38 
versus 1.6; P = 0.01), as well as the lower 
percentage of day-5 blastocysts (85% 
versus 96.8%; P = 0.01), reinforces 
the concept of the positive effect of 
the personalization of endometrial 
factor even with embryonic ‘inferiority’ 
(Supplementary Table 1).
Personalized medicine is still in its 
infancy in reproductive medicine, but 
most specialists in the field will agree 
that ‘one size does not fit all’. In fact, 
clinicians and embryologists have been 
evaluating precision medicine through 
assisted reproductive technology 
treatment for decades (Mol et al., 
2018), from the starting dose and 
dose adjustment of gonadotrophins in 
ovarian stimulation according to ovarian 
reserve, age and BMI; determination 
of oocyte retrieval timing based on 
ultrasound findings and oestradiol and 
progesterone levels; selection of the 
insemination and fertilization technique 
(ICSI, IVF, or both) according to sperm 
features and clinical background; 
or embryo selection based on 
morphological grading, chromosomal 
analysis of the cleavage embryos, or 
both, or blastocyst.
Interestingly, endometrial status at the 
time of embryo transfer was guided 
in recent decades by endometrial 
thickness assessed through transvaginal 
ultrasound together with administration 
or supplementation of progesterone 
or HCG as luteal phase support. 
Endometrial thickness, however, is 
not a diagnostic test for endometrial 
receptivity. Indeed, this approach has 
limited capacity to identify patients 
with low possibility to conceive after 
embryo transfer, except for atrophic 
or hyperplasic endometrium (Kasius 
et al., 2014). Therefore, the use of 
TABLE 2 – (continued)
PET (n = 141) FET (n = 148) Fresh embryo transfer (n = 145)
Warmed HRT embryo transfer data
 Days of oestradiol, n 15.5 ± 3.8c 16.6 ± 3.8c NA
 Endogenous progesterone levelsb 0.2 (0.03–1.4) 0.29 (0.05–11.03) NA
 Exogeneous progesterone administration, h 120 ± 14.4 117.8 ± 9.7 NA
 Exogeneous progesterone administration, h, range 65.2–163.4 (98.2) 66.4–151.2 (84.8) NA
 Time between ovarian stimulation and embryo transfer, months 3.2 ± 2.4c 2.1 ± 1.4d NA
Data are expressed as mean ± SD unless otherwise specified.
a Total number of indicated cases may differ from the excluded number of cases indicated in FIGURE 1 because some patients had more than one cause for exclusion.
b Progesterone value (ng/ml) before its administration is represented as median (interquartile range).
c,dStatistically significant differences between groups at the <0.05 level. Significant differences were found among groups in ovulation triggering (P = 0), embryo stage 
(cleavage embryo, P = 0.005), day of embryo development (P = 0.006), number of days of oestradiol (P = 0.03) and time between ovarian stimulation and embryo transfer 
(months) (P = 0.002). No significant differences were found in the other variables.
Analysis of variance, Bonferroni and two-sided Dunnett tests were used to compare numerical variables in the three groups, whereas Independent samples Student's t-test 
was used to compare quantity variables between group PET and FET regarding warmed HRT embryo transfer data. Chi-squared and Fisher's exact tests were used to com-
pare categorical variables.
FET, frozen embryo transfer; HMG, human menopausal gonadotrophin; HRT, hormone replacement therapy; ICSI, intracytoplasmic sperm injection; INVO, intravaginal 
culture of oocytes; PET, personalized embryo transfer; PGT-A, preimplantation genetic diagnosis for aneuploidy.
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endometrial thickness as an actionable 
biomarker to decide whether to cancel 
cycles, freeze all embryos or refrain from 
further IVF treatment is not justified 
based on the current data. Luteal phase 
supplementation starts around the time 
of oocyte retrieval after HCG trigger, 
although a start on the day of the oocyte 
retrieval does not improve clinical 
outcomes compared with a start 6 days 
later (Connell et al., 2015). Furthermore, 
much effort has been dedicated 
to comparing clinical results using 
different routes, dosages or duration of 
progesterone administration in IVF/ICSI 
cycles, in an endless pharmacological 
dispute, resulting in no evidence 
favouring any of them (Glujovsky et al., 
2010).
Local injury to the endometrium 
during the ERA biopsy is suggested to 
help increase implantation success in 
the subsequent month. We analysed 
clinical results according to time from 
endometrial biopsy for the ERA test 
to embryo transfer for a period of 9 
months, concluding that pregnancy rate 
and LBR were statistically non-significant 
throughout this period (Supplementary 
Table 4) and ruling out any beneficial or 
detrimental effect of the injury occurring 
at the endometrial biopsy. Similar findings 
were reported in a previous prospective 
study in patients who had experienced 
recurrent implantation failure, in which 
patients were followed after biopsy 
for ERA to transfer for a period of 6 
months; no improvement in reproductive 
outcomes was detected the month after 
endometrial biopsy (Ruiz-Alonso et al., 
2013). The discussion about the clinical 
value of endometrial scratching is coming 
to end after an RCT involving 1364 
women undergoing IVF reported that 
scratching did not result in a higher rate 
of live birth than no intervention (Lensen 
et al., 2019).
Critically, the objective diagnosis of the 
endometrial receptivity factor remains 
TABLE 3 REPRODUCTIVE OUTCOMES AT FIRST EMBRYO TRANSFER AND CUMULATIVE OUTCOMES DURING 1-YEAR 
FOLLOW-UP: INTENTION-TO-TREAT ANALYSIS
PET (n = 141) FET (n = 148) Fresh embryo 
transfer ET 
(n = 145)




P-value Relative risk 
(95% CI)
P-value
Transfers, n 132 137 138
Pregnancy rate, n (%) 83 (58.9) 73 (49.3) 84 (57.9) 1.19 (0.96 to 1.48) 0.12 1.02 (0.84 to 1.24) 0.9
Implantation rate, n (%) 88/201 (43.8) 80/220 (36.4) 97/225 (43.1) 1.20 (0.95 to 1.52) 0.14 1.02 (0.82 to 1.26) 0.92
Live birth rate n (%) 57 (40.4) 51 (34.5) 64 (44.1) 1.17 (0.87 to 1.58) 0.33 0.92 (0.70 to 1.20) 0.55
 Singleton 49/57 (86) 40/51 (78.4) 45/64 (70.3) 1.1 (0.92 to 1.31) 0.32 1.22 (1.01 to 1.48) 0.049
 Multiple (all twins) 8/57 (14) 11/51 (21.6) 19/64 (29.7) 0.65 (0.28 to 1.49) 0.32 0.47 (0.22 to 1) 0.049
Clinical miscarriages, n (%) 17/83 (20.5) 11/73 (15.1) 5/84 (5.9) 1.36 (0.68 to 2.71) 0.41 3.44 (1.33 to 8.90) 0.006
Biochemical pregnancies, n (%) 7/83 (8.4) 9/73 (12.3) 11/84 (13.1) 0.68 (0.27 to 1.74) 0.44 0.64 (0.26 to 1.58) 0.46
Ectopic pregnancies, n (%) 1/83 (1.2) 1/73 (1.4) 1/84 (1.2) 0.88 (0.06 to 13.82) 1 1.01 (0.06 to 15.92) 1
Elective termination of pregnancy, n (%) 1/83 (1.2) 0/73 (0.0) 1/84 (1.2)
Neonatal mortality, n (%) 0/83 (0.0) 1/73 (1.4) 0/84 (0.0)
Live birth lost to follow-up, n (%) 0 (0.0) 0 (0.0) 2/84 (2.4)
Patients with additional embryo transfers, 
n (%)
57 (40.4) 57(38.5) 42 (28.9) 1.05 (0.79-1.40) 0.81 1.40 (1.01 to 1.93) 0.047
Total additional cycles and transfers, n 150 130 110
Cumulative transfers, n 282 267 248
Pregnancies from additional embryo 
transfers, N
49 45 33
Cumulative pregnancy rate, n (%) 132/141 (93.6) 118/148 (79.7) 117/145 (80.7) 1.17 (1.07 to 1.29) 0.0005 1.16 (1.06 to 1.27) 0.0013
Cumulative live birth rate, n (%) 88/141 (62.4) 82/148 (55.4) 85/145 (58.6) 1.13 (0.93 to 1.37) 0.23 1.06 (0.88 to 1.28) 0.55
 Singleton 75/88 (85.2) 67/82 (81.7) 58/85 (68.2) 1.04 (0.91 to 1.19) 0.54 1.25 (1.06 to 1.48) 0.011
 Multiple (all twins) 13/88 (14.8) 15/82 (18.3) 27/85 (31.8) 0.81 (0.41 to 1.59) 0.54 0.47 (0.26 to 0.84) 0.011
Cumulative clinical miscarriages, n (%) 24/132 (18.2) 17/118 (14.4) 5/117 (4.3) 1.26 (0.71 to 2.23) 0.49 4.26 (1.68 to 10.79) 0.0006
Cumulative biochemical pregnancies, n 
(%)
19/132 (14.4) 16/118 (13.6) 23/117 (19.7) 1.06 (0.57 to 1.97) 1 0.73 (0.42 to 1.27) 0.31
Cumulative ectopic pregnancies, n (%) 1/132 (0.8) 1/118 (0.8) 1/117 (0.9) 0.89 (0.06 to 14.14) 1 0.89 (0.06 to 14.02) 1
Transfers per patient 2.63 ± 1.14 2.28 ± 0.70 2.62 ± 0.73 0.35 (–0.4 to 0.4) 0.1 0.01 (–0.43 to 0.45) 1
Values are expressed as mean ± SD unless otherwise specified. Fisher´s exact test (two-sided) was used to compare these results. Relative risk (95% CI) was calculated using 
the approximation of Katz. Independent-samples Student's t-test was applied when quantitative variables were compared; relative risk and 95% CI were calculated using 
Bonferroni and Dunnett T3 post hoc tests.
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neglected. Endometrial receptivity analysis 
was the first molecular test created for 
this purpose to assess a personalized 
clinical approach for the endometrial 
factor, aiming to improve clinical success 
from the endometrial perspective in 
patients who had experienced recurrent 
implantation failure (Ruiz-Alonso et al., 
2013; 2014; Hashimoto et al., 2017). 
As a next step, we tested in this RCT 
the quantitative relevance of the 
personalization of the endometrial factor 
in patients attending the infertility clinic 
at their first appointment. In the work-up 
of patients at the initial visit, we generally 
include general semen analysis, AMH, 
FSH, prolactin and thyroid-stimulating 
hormone. In this RCT, we also included 
the ERA test to objectively diagnose 
patients’ individual WOI and to guide 
PET; in this way, we could incorporate 
endometrial factor in the IVF process in 
addition to embryo quality. To avoid bias 
caused by variations in natural cycles, 
HRT was used for consistency. The ERA 
test, however, has been validated for 
natural and modified natural cycles (Diaz-
Gimeno et al., 2011; 2013; Ruiz-Alonso 
et al., 2013).
Embryo quality was assessed 
morphologically, and PGT-A was neither 
an inclusion nor an exclusion criterion. 
To address whether PGT-A might have 
biased study outcomes, we assessed 
the relevance of this factor in detail. 
First, the number of PGT-A cases did 
not significantly differ between the PET 
group and the other two arms. By ITT 
analysis, there were 13 PGT-A cases in a 
total of 434 randomized patients (3%): 
six out of 141 in the PET arm, four out of 
148 in the FET arm and three out of 145 
in the fresh embryo transfer arm (4.3%, 
2.7% and 2.1%, respectively; P = 0.6). By 
per protocol analysis, nine PGT-A cases 
in a total of 266 patients were included 
(3.4%): five out of 80 in the PET arm, 
three out of 92 in the FET arm and one 
out of 94 in the fresh embryo transfer 
arm (6.3%, 3.3% and 1.1%, respectively, 
P = 1.17). Therefore, in this RCT, the 
percentage of PGT-A embryo transfers 
was negligible (3.4%), and evenly 
distributed among the three arms of the 
study, i.e., not statistically significantly 
different.
Of note, per protocol, we registered 
a 5.4% miscarriage rate after fresh 
embryo transfer compared with 15.2% 
in PET and 14% in FET. According 
to the International Committee for 
Monitoring Assisted Reproductive 
Technologies world report (Dyer et al., 
2016), pregnancy loss in fresh embryo 
TABLE 4 REPRODUCTIVE OUTCOMES AT THE FIRST EMBRYO TRANSFER AND CUMULATIVE OUTCOMES DURING 
1-YEAR FOLLOW-UP: PER PROTOCOL ANALYSIS
PET (n = 80) FET (n = 92) Fresh embryo 
transfer 
(n = 94)




P-value Relative risk 
(95% CI)
P-value
Pregnancy rate, n (%) 58 (72.5) 50 (54.3) 55 (58.5) 1.33 (1.06 to 1.68) 0.01 1.24 (1 to 1.54) 0.057
Implantation rate, n (%) 63/110 (57.3) 60/139 (43.2) 58/150 (38.6) 1.33 (1.03 to 1.70) 0.03 1.48 (1.14 to 1.92) 0.004
Live birth rate, n (%) 45 (56.2) 39 (42.4) 43 (45.7) 1.33 (0.98 to 1.80) 0.09 1.23 (0.92 to 1.65) 0.17
 Singleton 40/45 (88.9) 30/39 (76.9) 33/43 (76.7) 1.16 (0.95 to 1.41) 0.16 1.16 (0.95 to 1.41) 0.16
 Multiple (all twins) 5/45 (11.1) 9/39 (23.1) 10/43 (23.2) 0.48 (0.18 to 1.32) 0.16 0.48 (0.18 to 1.28) 0.16
Clinical miscarriages, n (%) 9/58 (15.5) 7/50 (14) 3/55 (5.4) 1.11 (0.44 to 2.76) 1 2.84 (0.81 to 9.97) 0.13
Biochemical pregnancies, n (%) 4/58 (6.9) 4/50 (8) 8/55 (14.5) 0.86 (0.23 to 3.27) 1 0.47 (0.15 to 1.49) 0.23
Ectopic pregnancies, n (%) 0 (0.0) 0 (0.0) 1 (1.8)
Patients with surplus embryo transfers, n 
(%)
19 (23.7) 16 (17.4) 4 (4.2)
Total surplus embryo transfers, n 39 18 10
Cumulative transfers, n 119 110 104
Pregnancies from surplus embryo 
transfers, n
18 15 4
Cumulative pregnancy rate, n (%) 76/80 (95) 65/92 (70.6) 59/94 (62.8) 1.34 (1.17 to 1.55) <0.0001 1.51 (1.28 to 1.78) <0.0001
Cumulative live birth rate, n (%) 57 (71.2) 51 (55.4) 46 (48.9) 1.28 (1.02 to 1.62) 0.04 1.46 (1.13 to 1.87) 0.003
 Singleton 51/57 (89.5) 41/51 (80.4) 34/46 (73.9) 1.11 (0.95 to 1.31) 0.28 1.21 (1 to 1.47) 0.066
 Multiple (all twins) 6/57 (10.5) 10/51 (19.6) 12/46 (26.1) 0.54 (0.21 to 1.37) 0.28 0.40 (0.16 to 0.99) 0.066
Cumulative clinical miscarriages, n (%) 10/76 (13.2) 8/65 (12.3) 3/59 (5.1) 1.07 (0.45 to 2.55) 1 2.59 (0.75 to 8.99) 0.15
Cumulative biochemical pregnancies, n (%)9/76 (11.8) 6/65 (9.2) 9/59 (15.3) 1.28 (0.48 to 3.41) 0.78 0.78 (0.33 to 1.83) 0.62
Cumulative ectopic pregnancies, n (%) 0 (0.0) 0 (0.0) 1/59 (1.7)
Transfers per patient 3.05 ± 1.61 2.13 ± 0.34 3.5 ± 1.29 0.92 (–0.11 to 1.97) 0.09 –0.45 (–2.13 to 1.24) 1
Values are expressed as mean ± SD unless otherwise specified. Fisher's exact test (two-sided) was used to compare these results. Relative risk (95% CI) was calculated using 
the approximation of Katz. Independent samples Student's t-test was applied when quantitative variables were compared; relative risk and 95% CI were calculated using 
Bonferroni and Dunnett T3 post hoc tests.
FET, frozen embryo transfer; PET, personalized embryo transfer.
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transfer cycles occurred at a rate of 
21.8% (2008), 21.1% (2009) and 20.2% 
(2010). Corresponding early pregnancy 
loss rates for FET were 28.9% (2008), 
25.4% (2009) and 25.2% (2010). On 
the basis of these data, the unexpected 
5.4% miscarriage rate after fresh embryo 
transfer was below the rate reported in 
published research worldwide. We are 
unsure how to explain it, but this finding 
would be expected to bias the results 
toward favouring fresh embryo transfer 
versus the other two arms of the study. 
Nevertheless, biochemical pregnancies 
occurred in eight out of 55 (14.5%) in the 
fresh embryo transfer group higher than 
PET (6.9%) and FET (8%), balancing the 
total pregnancy losses of around 20% in 
all arms (22.1% in PET, 22% in FET and 
19.9% in fresh embryo transfer). This 
observation suggests that biochemical 
pregnancies might be a reflection of the 
endometrial status.
In the PET arm, 30 patients (37.5%) had 
a diagnosis of WOI displacement, and 
PET was carried out with a different 
TABLE 5 OBSTETRICAL, DELIVERY AND NEONATAL OUTCOMES: PER PROTOCOL ANALYSIS
PET (n = 80) FET (n = 92) Fresh embryo transfer 
(n = 94)















Ovarian hyperstimulation 80 0 (0.0) 92 0 (0.0) 94 1 (1.1)
Obstetrical outcomes 45 39 43
 Gestational diabetes 2 (4.4) 1 (2.6) 1 (2.3)
 High blood pressure 1 (2.2) 0 (0.0) 0 (0.0)
 Placenta previa 1 (2.2) 1 (2.6) 0 (0.0)
 Retrocorial haematoma 0 (0.0) 1 (2.6) 1 (2.3)
 Abruption 1 (2.2) 0 (0.0) 0 (0.0)
 Vasa previa 1 (2.2) 0 (0.0) 0 (0.0)
 Still birth 1 (2.2) 1 (2.6) 0 (0.0)
Type of delivery 40 35 43










Neonatal outcomesa 40 35 43
 Neonatal mortality 0 (0.0) 1 (2.9) 0 (0.0)





 Preterm birth <37 
weeks





 Birth weight, g 23 3170.6 ± 
646.9







 Birth weight in single-
tons
17 3484.4 ± 
321.6







 Birth weight in twins 6 2281.7 ± 476.7 16 2436.2 ± 
444.9






























 Congenital anomalies 0 (0.0) 0 (0.0) 0 (0.0)
Values are given as mean ± SD unless otherwise specified. Fisher´s exact test (two-sided) was used to compare qualitative variables; relative risk (95% CI) was calculated 
using the approximation of Katz. Independent samples Student's t-test was used to compare quantitative variables; relative risk and 95% CI were calculated using Bonferroni 
and Dunnett T3 post hoc tests.
a Percentage is ratio of total deliveries.
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timing than for standard WOI; 17 out 
30 patients (56.7%) achieved a live birth 
in their first attempt. Similar clinical 
outcome was obtained for patients 
in whom the WOI was present at 
the expected timing (Supplementary 
Table 5). Considering that there should 
be a similar percentage of patients with 
displaced WOI in the other study arms 
that were blind to the endometrial 
factor assessment, this might explain the 
differential results obtained.
Finally, using the clinical results obtained 
in this RCT, we conducted a cost-
effectiveness study per live birth with 
reference to economic figures for 
Europe and the USA, where the IVF 
costs are quite different. This assessment 
demonstrated that the estimated 
cost per live birth in the PET arm is 
approximately 17% less compared with 
the most expensive FET and 25% more 
than the less costly FET (15% and 17%, 
respectively in the USA) (TABLE 6).
The main limitation of our study is 
the unexpected 50% patient drop-
out rate versus 30% initially planned. 
This situation has rendered the study 
underpowered to detect statistical 
significance by ITT analysis in the PET 
arm versus FET and fresh embryo 
transfer, except for higher CLBR. This 
sample size affected the per protocol 
analysis; although the analysis detected 
a 13.8 and 10.5-percentage points 
increase in LBR in the PET group versus 
FET and fresh embryo transfer at the 
first embryo transfer, the difference 
was not significant because the study 
was powered to detect statistical 
differences for a 15-percentage point 
increase in the primary and secondary 
outcomes. Second, in the historical 
setting in which this RCT was designed, 
ERA was carried out using microarray 
technology with early algorithms, and 
in some cases two endometrial biopsies 
were needed for diagnosis. At the time 
of publication, ERA is being done by 
next-generation sequencing combined 
with refined algorithms informed by 
the analysis and clinical follow-up of 
more than 50,000 endometrial samples 
worldwide; additionally, only one 
endometrial biopsy is needed. Because 
of the indicated constraints of the 
study, we are conducting a new ERA 2.0 
RCT, in which the current sequencing 
technology and refined algorithms will 
be included together with proper power 
of the study.
In conclusion, to the best of our 
knowledge, this is the first RCT aiming 
to provide proof-of-principle evidence 
for the potential of using a personalized 
diagnosis of the endometrial factor in 
the work-up of the infertile couple at the 
first appointment. While the ITT analysis 
shows no beneficial effect of the ERA test 
except for a statistically significant CPR 
compared with FET and fresh embryo 
transfer, the per protocol analysis 
demonstrates a significant improvement 
in pregnancy rates at the first and 
cumulative rates up to 12 months, and 
implantation rates at the first attempt, 
indicating the potential of the ERA test 
to diagnose the endometrial factor in the 
work-up of the infertile couple. These 
findings need to be confirmed in a larger 
randomized clinical trial.
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TABLE 6 COST-EFFECTIVENESS ESTIMATION PER LIVE-BORN BABY AT THE FIRST ATTEMPT
PET (n = 80) FET (n = 92) Fresh embryo transfer (n = 94)
Deliveries with at least one live birth at 
the first attempt, n
45 39 43
EU, € USA, $ EU, € USA, $ EU, € USA, $
IVF laboratory cost 5190a 11,825a 5190a 11,825a 5590b 12,325b
Drug cost 1700c 5500c 1600 d 4700d 1580 e 4500e
Vitrification cost 1100f 1,375f 1100f 1375f – –
Additional cost in PET and FET 2050 g 3500g 2050 g 3500g – –
Cost of ERA 710 795 – – – –
Mock cycle 250h 1000h – – – –
Total cost per embryo transfer 11,000 23,995 9940 21,400 7170 16,825
Estimated cost of a delivery with at least one live 
birth at the first attempt
19,555 42,658 23,448 50,482 15,674 36,780
Data are expressed as mean.
The detailed cost presented in TABLE 1 corresponded to the cost of the different steps of the treatment in the patients included in the study (Euros and Dollars).
a Monitoring (bloodwork and ultrasounds), retrieval, anaesthesia, intracytoplasmic sperm injection, extended culture and male partner seminogram.
b Monitoring (bloodwork and ultrasounds), retrieval, anaesthesia, intracytoplasmic sperm injection, extended culture, male partner seminogram and transfer.
c Gonadotrophins, HCG, progesterone x2, oestradiol x2.
d Gonadotrophins, HCG, progesterone x1, oestradiol x1.
e Gonadotrophins, HCG, progesterone x1.
f Cryopreservation and storage.
g Monitoring (bloodwork and ultrasounds), warming and transfer.
h Monitoring (bloodwork and ultrasounds) and biopsy.ERA, endometrial receptivity analysis; FET, frozen embryo transfer; PET, personalized embryo transfer.
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